Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is Vesugen? KED Identity and Laboratory Documentation

A research-use identity note on Vesugen as the KED tripeptide, with attributed 5xFAD mouse-model findings and tissue-specific interpretation limits.

What Is Vesugen? KED Identity and Laboratory Documentation

Vesugen is a short bioregulator peptide investigated in vascular-tissue and cellular-aging research models. The original overview of this page asks three questions: vascular-model research context, tissue-specific interpretation limits, and sequence, content, and lot traceability.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

Sequence identity and research context

Khavinson and colleagues mapped the name Vesugen to the tripeptide KED in a systematic review of peptide regulation of gene expression (Khavinson et al., 2021, Molecules). KED is not KE (Vilon) and is not EDR (Pinealon). A class overview is at What Are Bioregulator Peptides?; an EDR identity note is at What Is Pinealon?.

The original page framed Vesugen in vascular-tissue and cellular-aging models. The papers verified for this draft support the KED name mapping and, separately, reported findings for KED in a mouse model of Alzheimer’s disease, as cited below. A KED-specific vascular-tissue primary paper was not independently verified here. Vascular endpoints should not be assumed from the name alone, and they should not be borrowed from a different sequence.

Tissue-specific interpretation limits

Khavinson, Ilina, Kraskovskaya, and colleagues reported neuroprotective effects of the tripeptides they studied in a 5xFAD mouse model of Alzheimer’s disease. They stated that KED and EDR peptides prevented dendritic spine loss in 5xFAD-M mice, and that KED administration in 5xFAD mice from two to four months of age tended to increase neuroplasticity (Khavinson et al., 2021, Pharmaceuticals). Those are attributed mouse-model observations. This draft does not transcribe dose, route, or schedule from that paper as a regimen, and it does not treat a neuroplasticity finding as a vascular or clinical outcome.

Sequence, content, and lot traceability

A three-letter code is not a complete specification until the sequence, content, and lot report agree. Methods should be suited to a short peptide. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, and lot traceability apply independently to this row.

Vesugen was not found as a standalone published item in Velnacor’s current research-material catalog listing used for this draft. Use the product directory and the COA Library, then confirm whether a current SKU exists and which lot documents apply in the inquiry. For packing at supply scale, see wholesale peptides.

Tissue context is the main interpretation limit. A vascular-model question and a dendritic-spine or neuroplasticity question are not the same experiment, even when both are discussed under a short-peptide heading. If a laboratory is actually asking a vascular question, the protocol should name that tissue and those endpoints, and it should not lean on the 5xFAD mouse observations as if they answered it. Conversely, the mouse-model findings cited here should not be rewritten as vascular or human outcomes.

Selected published literature

  1. Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. PubMed 34834147. Open access: PMC8619776. Systematic review; cited for the KED/Vesugen name mapping, not as a use instruction.
  2. Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective effects of tripeptides—epigenetic regulators in mouse model of Alzheimer’s disease. Pharmaceuticals. 2021;14(6):515. doi:10.3390/ph14060515. PubMed 34071923. Cited for attributed 5xFAD mouse-model observations; dose and route in the paper are not restated here as instructions.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0